Pharvaris says EC grants orphan designation to deucrictibant

Pharvaris (PHVS) announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. FDA previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.